Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1% - Here's What Happened

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s share price fell 1% on Monday . The stock traded as low as $57.00 and last traded at $57.52. 2,797,482 shares were traded during trading, a decline of 68% from the average session volume of 8,802,935 shares. The stock had previously closed at $58.08.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $135.00.

Novo Nordisk A/S Stock Up 3.6 %

The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $278.45 billion, a PE ratio of 18.86, a PEG ratio of 0.90 and a beta of 0.61. The business has a fifty day moving average of $74.67 and a 200 day moving average of $90.76.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a $0.7874 dividend. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio (DPR) is 49.54%.

Institutional Investors Weigh In On Novo Nordisk A/S

Large investors have recently modified their holdings of the company. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 3.9% during the first quarter. International Assets Investment Management LLC now owns 20,676 shares of the company's stock worth $1,436,000 after purchasing an additional 768 shares in the last quarter. Balboa Wealth Partners boosted its position in shares of Novo Nordisk A/S by 2.5% during the 1st quarter. Balboa Wealth Partners now owns 11,018 shares of the company's stock worth $765,000 after acquiring an additional 273 shares in the last quarter. Family Legacy Inc. increased its holdings in shares of Novo Nordisk A/S by 2.2% in the 1st quarter. Family Legacy Inc. now owns 18,969 shares of the company's stock valued at $1,317,000 after acquiring an additional 412 shares during the last quarter. Sava Infond d.o.o. raised its position in shares of Novo Nordisk A/S by 11.9% during the 1st quarter. Sava Infond d.o.o. now owns 20,700 shares of the company's stock worth $1,437,000 after acquiring an additional 2,200 shares in the last quarter. Finally, Gallagher Capital Advisors LLC lifted its stake in Novo Nordisk A/S by 24.7% during the first quarter. Gallagher Capital Advisors LLC now owns 19,064 shares of the company's stock worth $1,324,000 after purchasing an additional 3,780 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.